The content is available as a PDF (334.4 KB).
letter . 2021 May 6:jiab238. doi: 10.1093/infdis/jiab238
Response to Panda et al
M Rieder
1,2,4,✉, D Duerschmied
1,2, C Bode
1,2, A Lother
1,2,3
M Rieder
1Heart Center Freiburg University, Department of Cardiology
and Angiology I, Faculty of Medicine, University of Freiburg,
Freiburg, Germany
2Department of Medicine III (Interdisciplinary Medical
Intensive Care), Medical Center, Faculty of Medicine, University
of Freiburg, Freiburg, Germany
4Department of Cardiology, Inselspital, Bern University
Hospital, Bern, Switzerland
Find articles by M Rieder
D Duerschmied
1Heart Center Freiburg University, Department of Cardiology
and Angiology I, Faculty of Medicine, University of Freiburg,
Freiburg, Germany
2Department of Medicine III (Interdisciplinary Medical
Intensive Care), Medical Center, Faculty of Medicine, University
of Freiburg, Freiburg, Germany
Find articles by D Duerschmied
C Bode
1Heart Center Freiburg University, Department of Cardiology
and Angiology I, Faculty of Medicine, University of Freiburg,
Freiburg, Germany
2Department of Medicine III (Interdisciplinary Medical
Intensive Care), Medical Center, Faculty of Medicine, University
of Freiburg, Freiburg, Germany
Find articles by C Bode
A Lother
1Heart Center Freiburg University, Department of Cardiology
and Angiology I, Faculty of Medicine, University of Freiburg,
Freiburg, Germany
2Department of Medicine III (Interdisciplinary Medical
Intensive Care), Medical Center, Faculty of Medicine, University
of Freiburg, Freiburg, Germany
3Institute of Experimental and Clinical Pharmacology and
Toxicology, Faculty of Medicine, University of Freiburg, Freiburg,
Germany
Find articles by A Lother
1Heart Center Freiburg University, Department of Cardiology
and Angiology I, Faculty of Medicine, University of Freiburg,
Freiburg, Germany
2Department of Medicine III (Interdisciplinary Medical
Intensive Care), Medical Center, Faculty of Medicine, University
of Freiburg, Freiburg, Germany
3Institute of Experimental and Clinical Pharmacology and
Toxicology, Faculty of Medicine, University of Freiburg, Freiburg,
Germany
4Department of Cardiology, Inselspital, Bern University
Hospital, Bern, Switzerland
✉
Corresponding Author: Marina Rieder marina.baeuml@universitaets-herzzentrum.de
Received 2021 Apr 25.
Keywords: COVID-19, SARS-CoV-2, Progranulin
© The Author(s) 2021. Published by Oxford University Press
for the Infectious Diseases Society of America. All rights reserved. For
permissions, e-mail: journals.permissions@oup.com.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
PMCID: PMC8135912 PMID: 33955472
See the article "Granulin rs5848 (C>T) polymorphism is associated with SARS-CoV-2
infection and mortality", jiab237.